# OCT 1 1 2007

# Nanosphere

510(k) Summary

This summary of the $5 1 0 ( { \sf k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1900 and CFR 807.92.

# 510(k) number:

K070597

# Summary preparation date:

October 5, 2007

# Submitted by:

Nanosphere, Inc.   
4088 Commercial Avenue   
Northbrook, IL 60062   
Phone: 847-400-9000 Fax: 847-400-9199

# Contact:

Sue Kent - Manager, Clinical & Regulatory Affairs

# Proprietary names:

For instrument: Verigene® System

For the assays: Verigene HC Nucleic Acid Test Verigene F5 / F2 / MTHFR Nucleic Acid Test Verigene F5 / F2 Nucleic Acid Test Verigene F2 Nucleic Acid Test Verigene F5 Nucleic Acid Test Verigene MTHFR Nucleic Acid Test

# Common names:

For the instrument: Bench-top molecular diagnostics workstation

For the assays:   
F2, FII, Factor II, coagulation factor II, prothrombin F5, FV, Factor V, coagulation factor V.   
MTHFR, methylenetetrahydrofolate reductase Hypercoagulation panel   
HC panel

# Device descriptions:

The Verigene System is an in vitro diagnostic device for processing and genotyping multiple genes in a DNA sample. The Verigene System consists of two instruments, the Verigene Processor and the Verigene Reader, and utilizes single-use, disposable Test Cartridges to process and genotype multiple genes in a DNA sample in approximately $1 \%$ hours.

Clinicians use one or more of the three genes (F5, F2, MTHFR) and their associated single nucleotide polymorphisms (SNPs) to help diagnose patients' hereditary contributory factors in forming blood clots (thrombi). On the Verigene System, hypercoagulation testing can include one or more of three genotypes that are associated with hypercoagulation (i.e., thrombophilia). These tests use DNA, extracted from human blood, to detect certain genetic mutations (SNPs).

The analysis sequence is the same for each of the three tests (i.e., F2, F5, MTHFR). After extracted and purified DNA, mixed with hybridization buffer, is loaded into the sample well of the Test Cartridge, it is ready for processing and is inserted into the Verigene Processor. An internal barcode reader reads the cartridge ID and sends the information to the Verigene Reader. From this information, the Verigene Reader establishes the hybridization parameters and starts the hybridization process.

The genotyping process occurs with a hybridization of the target analyte to a synthetic gene-specific oligonucleotide capture strand on the Test Cartridge's substrate. A synthetic mediator target-specific oligonucleotide is included with the test-specific sample buffer to form a hybridization "sandwich" with the gene sequence of interest. Washing steps following the target hybridization remove the unbound DNA from the hybridization chamber. A probe, composed of a gold nanoparticle with covalently bound oligonucleotides complementary to a sequence on the intermediate oligonucleotide, is introduced after the target wash. After the probe hybridization is completed, a series of washing steps remove the unbound probe from the hybridization chamber. A two-part signal enhancement reagent is added to the hybridization chamber and reacts with the gold nanoparticle to amplify the signal for the Verigene Reader scanning and analysis.

Upon completion of the genotyping process, the user removes the Test Cartridge from the Verigene Processor which is now ready for the next test.

Once the reagent portion of the Test Cartridge is removed by the user, the substrate is inserted into the Verigene Reader. The Verigene Reader illuminates the signal-enhanced nanoparticles specifically bound to either the wild type or mutant captures for the gene. A photosensor reads the relative brightness of each spot and the Verigene Reader outputs a result based on relative levels of brightness of the wild type to mutant signals.

# Intended uses:

The Verigene® System is a bench-top molecular diagnostics workstation that automates the in vitro diagnostic analysis and detection of nucleic acids using gold nanoparticle probe technology. The Verigene System is intended to be used by experienced laboratory professionals with training on basic laboratory techniques and on the use of the system components.

The Verigene F5 Nucleic Acid Test is an in vitro diagnostic for the detection and genotyping of a single point mutation (G to A at position 1691; also known as Factor V Leiden) of the human Factor V gene (F5; Coagulation Factor V gene) in patients with suspected thrombophilia, from isolated genomic DNA obtained from whole blood samples. The test is intended to be used on the Verigene System.

The Verigene F2 Nucleic Acid Test is an in vitro diagnostic for the detection and genotyping of a single point mutation (G to A at position 20210) of the human Factor II gene ( $F 2 ;$ prothrombin gene) in patients with suspected thrombophilia, from isolated genomic DNA obtained from whole blood samples. The test is intended to be used on the Verigene System.

The Verigene MTHFR Nucleic Acid Test is an in vitro diagnostic for the detection and genotyping of a single point mutation (C to T at position 677) of the human 5,10 methylenetetrahydrofolate reductase gene (MTHFR) in patients with suspected thrombophilia, from isolated genomic DNA obtained from whole blood samples. The test is intended to be used on the Verigene System.

# Predicate devices:

For the instrument: Roche Diagnostics Corporation LightCycler® Instrument (K033734)

For the assays: Roche Diagnostics Corporation Factor V Leiden Kit (K033607) Roche Diagnostics Corporation Factor II (Prothrombin) G20210A Kit (K033612)

Comparison to Technological Features of the Predicate Device

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Verigene System</td><td rowspan=1 colspan=1>LightCycler Instrument</td></tr><tr><td rowspan=1 colspan=1>Enzymaticmanipulation of sample</td><td rowspan=1 colspan=1>No(chemical amplification ofreporter signal</td><td rowspan=1 colspan=1>Yes(DNA amplification viaPCR)</td></tr><tr><td rowspan=1 colspan=1>Detection procedure</td><td rowspan=1 colspan=1>Single-image sensorwhere nanoparticles areilluminated using a fixed-wavelength light source</td><td rowspan=1 colspan=1>Optical detection ofstimulated fluorescence</td></tr><tr><td rowspan=1 colspan=1>Heating method</td><td rowspan=1 colspan=1>1) Sonication horn forsample denaturation) Temperature-controlled heat block incontact with substrate</td><td rowspan=1 colspan=1>Hot air cycling with glasscapillaries</td></tr><tr><td rowspan=1 colspan=1>Detection chemistry</td><td rowspan=1 colspan=1>SNP discrimination viaoligonucleotide probes;detection via evanescentwave light scatter withnanoparticles</td><td rowspan=1 colspan=1>Paired hybridizationprobes usingfluorescence resonanceenergy transfer (FRET)</td></tr><tr><td rowspan=1 colspan=1>Primary operationalcomponents</td><td rowspan=1 colspan=1>Integrated hybridization/washing forwalkaway assayhybridization anddetection.Automated array imageacquisition and resultsinterpretation.</td><td rowspan=1 colspan=1>Integrated thermocyclerand microvolumefluorimeter for walkawayPCR amplification anddetection.</td></tr><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>Purified nucleic acids</td><td rowspan=1 colspan=1>Purified nucleic acids</td></tr><tr><td rowspan=1 colspan=1>Specimen preparation</td><td rowspan=1 colspan=1>DNA isolation performedoff-line. Fragmentation ofDNA performedonboard.</td><td rowspan=1 colspan=1>Performed off line</td></tr><tr><td rowspan=1 colspan=1>Sample positions</td><td rowspan=1 colspan=1>4-32</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>Sample size</td><td rowspan=1 colspan=1>25 μl</td><td rowspan=1 colspan=1>10-20 μL in glasscapillaries</td></tr><tr><td rowspan=1 colspan=1>Number of opticaldetection channels</td><td rowspan=1 colspan=1>One fixed-wavelengthimager</td><td rowspan=1 colspan=1>Three with fixedwavelengths (530 nm,640 nm,710nm)</td></tr><tr><td rowspan=1 colspan=1>Analysis Time</td><td rowspan=1 colspan=1>2 minutes</td><td rowspan=1 colspan=1>Detection occurs atdefined intervals duringPCR cycle and can beviewed in real-time</td></tr><tr><td rowspan=1 colspan=1>User interface</td><td rowspan=1 colspan=1>Embedded softwarein closed system,integrated graphical userinterface.</td><td rowspan=1 colspan=1>PC with instrument-specific software(LightCycler version 3.5o higher)</td></tr></table>

Performance characteristics for Verigene F5 / F2 / MTHFR Nucleic Acid Tests:

# Reproducibility Study #1:

Three DNA samples, that had been whole genome amplified, were tested in duplicate twice per day by two operators at each of three test sites. Six lots of test cartridges were utilized (two lots at each site). Site 1 performed this testing for 10 non-consecutive days; Sites 2 and 3 performed the testing for 5 nonconsecutive days.

<table><tr><td colspan="1" rowspan="1">F5</td><td colspan="1" rowspan="1">Site</td><td colspan="1" rowspan="1">Correct Calls (%)</td><td colspan="1" rowspan="1">No Calls (%)</td><td colspan="1" rowspan="1">Mis-calls (%)</td></tr><tr><td colspan="1" rowspan="1">Operator A</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">117 (99.2%)*</td><td colspan="1" rowspan="1">1 (0.8%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator B</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">114(99.1%)*</td><td colspan="1" rowspan="1">1 (0.9%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator C</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">59 (98.3%)</td><td colspan="1" rowspan="1">1 (1.7%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator D</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">59 (98.3%)</td><td colspan="1" rowspan="1">1 (1.7%)</td><td colspan="1" rowspan="1">0(0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator E</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">58(100.0%)*</td><td colspan="1" rowspan="1">0(0.0%</td><td colspan="1" rowspan="1">0 (0.0%</td></tr><tr><td colspan="1" rowspan="1">Operator F</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">57 (96.6%)*</td><td colspan="1" rowspan="1">2 (3.4%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">F2</td><td colspan="1" rowspan="1">Site</td><td colspan="1" rowspan="1">Correct Calls (%)</td><td colspan="2" rowspan="1">No Calls (%)</td><td colspan="1" rowspan="1">Mis-calls (%)</td></tr><tr><td colspan="1" rowspan="1">Operator A</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">117 (99.2%)*</td><td colspan="2" rowspan="1">1 (0.8%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator B</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">114 (99.1%)*</td><td colspan="2" rowspan="1">1 (0.9%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator C</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">58 (96.7%)</td><td colspan="2" rowspan="1">2 (3.3%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator D</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">59 (98.3%)</td><td colspan="2" rowspan="1">1 (1.7%)</td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator E</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">58(100.0%)*</td><td colspan="1" rowspan="1">0(0.0%)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0 (0.0%)</td></tr><tr><td colspan="1" rowspan="1">Operator F</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">55 (93.2%)*</td><td colspan="1" rowspan="1">4 (6.8%)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0 (0.0%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1>MTHFR</td><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Correct Calls (%)</td><td rowspan=1 colspan=1>No Calls (%)</td><td rowspan=1 colspan=2>Mis-calls (%)</td></tr><tr><td rowspan=1 colspan=1>Operator A</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>117 (99.2%)*</td><td rowspan=1 colspan=1>1 (0.8%)</td><td rowspan=1 colspan=2>0(0.0%)</td></tr><tr><td rowspan=1 colspan=1>Operator B</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>113 (98.3%)*</td><td rowspan=1 colspan=1>2(1.7%)</td><td rowspan=1 colspan=2>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Operator C</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>58 (96.7%)</td><td rowspan=1 colspan=1>2 (3.3%)</td><td rowspan=1 colspan=2>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Operator D</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>58 (96.7%)</td><td rowspan=1 colspan=1>2 (3.3%)</td><td rowspan=1 colspan=2>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Operator E</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>58 (100.0%)*</td><td rowspan=1 colspan=1>0(0.0%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Operator F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>56 (94.9%)*</td><td rowspan=1 colspan=1>3 (5.1%)</td><td rowspan=1 colspan=2>0 (0.0%)</td></tr></table>

\*Ten cartridges (7 at Site 1 and 3 at Site 3) failed to run.

# Reproducibility Study #2:

A subsequent reproducibility testing included 4 studies, each using a different DNA sample extracted from fresh whole blood by the operators at 3 sites.

<table><tr><td rowspan=1 colspan=1>Study Description</td><td rowspan=1 colspan=4>Summary of Results</td></tr><tr><td rowspan=7 colspan=1>Each of the three test sites ran thesame sample in duplicate.</td><td rowspan=1 colspan=1>3 Sites</td><td rowspan=1 colspan=1>F5</td><td rowspan=1 colspan=1>F2</td><td rowspan=1 colspan=1>MTHFR</td></tr><tr><td rowspan=2 colspan=1>Site 1</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=2 colspan=1>Site 2</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=2 colspan=1>Site 3</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr></table>

<table><tr><td rowspan=7 colspan=1>One operator analyzed the samesample in duplicate each day forthree days.</td><td rowspan=1 colspan=1>3 Days</td><td rowspan=1 colspan=1>F2</td><td rowspan=1 colspan=1>F5</td><td rowspan=1 colspan=1>MTHFR</td></tr><tr><td rowspan=2 colspan=1>Day 1</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td></tr><tr><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td></tr><tr><td rowspan=2 colspan=1>Day 2</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td></tr><tr><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td></tr><tr><td rowspan=2 colspan=1>Day 3</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td></tr><tr><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td></tr></table>

<table><tr><td rowspan=7 colspan=1>Three operators at one site eachanalyzed the same sample induplicate.</td><td rowspan=1 colspan=1>3Operators</td><td rowspan=1 colspan=1>F2</td><td rowspan=1 colspan=1>F5</td><td rowspan=1 colspan=1>MTHFR</td></tr><tr><td rowspan=2 colspan=1>Operator 1</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=2 colspan=1>Operator 2</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=2 colspan=1>Operator 3</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>HET</td></tr></table>

Additional performance characteristics for Verigene F5 / F2 / MTHFR Nucleic Acid Tests:   

<table><tr><td rowspan=1 colspan=1>Study Description</td><td rowspan=1 colspan=4>Summary of Results</td></tr><tr><td rowspan=7 colspan=1>One operator analyzed the samesample in duplicate using three lotsof reagents.</td><td rowspan=1 colspan=1>3 ReagentLots</td><td rowspan=1 colspan=1>F2</td><td rowspan=1 colspan=1>F5</td><td rowspan=1 colspan=1>MTHFR</td></tr><tr><td rowspan=2 colspan=1>Lot 1cartridge:082107001Abuffer:082207001C</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=2 colspan=1>Lot 2cartridge:082707001Cbuffer:050707001D</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=2 colspan=1>Lot 3cartridge:082807001Abuffer:082707001D</td><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td></tr><tr><td rowspan=1 colspan=1>HET</td><td rowspan=1 colspan=1>WT</td><td rowspan=1 colspan=1>HET</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Verigene F5 NucleicAcid Test</td><td rowspan=1 colspan=1>Verigene F2 NucleicAcid Test</td><td rowspan=1 colspan=1>Verigene MTHFRNucleic Acid Test</td></tr><tr><td rowspan=1 colspan=1>Analytical sensitivity(LDL)</td><td rowspan=1 colspan=1>40 ng/μL</td><td rowspan=1 colspan=1>40 ng/μL</td><td rowspan=1 colspan=1>40 ng/μL</td></tr><tr><td rowspan=1 colspan=1>Call rate</td><td rowspan=1 colspan=1>98.3%(282 out of 287 calls made)</td><td rowspan=1 colspan=1>94.7%(272 out of 287 calls made)</td><td rowspan=1 colspan=1>93.4%(268 out of 287 calls made)</td></tr><tr><td rowspan=1 colspan=1>Diagnostic sensitivityspecificity</td><td rowspan=1 colspan=1>100%(95%CI =98.9 to 100%)100%(95%CI =98.9 to 100%)</td><td rowspan=1 colspan=1>100%(95%Cl =98.9 to 100%)100%(95%Cl =98.9 to 100%)</td><td rowspan=1 colspan=1>100%(95%Cl =98.9 to 100%)100%(95%Cl =98.9 to 100%)</td></tr><tr><td rowspan=1 colspan=1>Precautions andwarnings</td><td rowspan=1 colspan=1>In the F5 gene,additional rare mutationsother than the 1691G&gt;Abase change have beenobserved. Some ofthese mutations occur inregions covered by theoligonucleotide probesused in the test. Thepresence of one or moreof these mutations maylead to an unknownresult. NOTE: none ofthe mutations listedabove have been linkedto APC resistance.This test should not beused alone to diagnosethrombophilias. It isrecommended thatactivated protein C(APC) testing be donealongside the genetictest.</td><td rowspan=1 colspan=1>In the F2 gene,additional raremutations other than the20210G&gt;A base changehave been observed.Some of thesemutations occur inregions covered by theoligonucleotide probesused in the test. Thepresence of one or moreof these mutations maylead to an unknownresult.This test should not beused alone to diagnosethrombophilias.</td><td rowspan=1 colspan=1>In the MTHFR gene,additional rare mutationsother than the 677C&gt;Tbase change have beenobserved. Some ofthese mutations occur inregions covered by theoligonucleotide probesused in the test. Thepresence of one or moreof these mutations maylead to an unknownresult.This test should not beused alone to diagnosethrombophilias.</td></tr></table>

<table><tr><td>Interferences</td><td>Performance not affected by magnetic beads heparin hemoglobin Other possible interferences are not known.</td></tr><tr><td>Reagent stability</td><td>The Test Cartridges are to be stored from 2°C to 8°C until the expiration date printed on the label. The HC Sample Buffer is to be stored from 2°C to 8°C until the expiration date printed on the label. Neither the Test Cartridges nor the Sample Buffer can be frozen.</td></tr></table>

Verigene® is a registered trademark of Nanosphere, Inc.   
LightCycler® is a registered trademark of Roche Diagnostics Corp.

# MAR 24 2009

Nanosphere, Inc.   
c/o Gregory W. Shipp, M.D.   
Chief Medical Officer, VP of Medical and Regulatory Affairs and Quality Assurance 4088 Commercial Avenue   
Northbrook, IL 60062

Re: k070597 Trade/Device Name: Verigene $\textsuperscript { \textregistered }$ F5 Nucleic Acid Test Verigene $\textsuperscript { \textregistered }$ F2 Nucleic Acid Test Verigene $\textsuperscript { \textregistered }$ MTHFR Nucleic Acid Test Verigene $\mathfrak { Q }$ System Regulation Number: 21 CFR 864.7280 21 CFR 862.2570 Regulation Name: Factor V Leiden DNA mutation detection systems Instrumentation for clinical multiplex test systems Regulatory Class: Class Ⅱ Product Code: NPQ, NPR, OMM, NSU Dated: October 5, 2007 Received: October 9, 2007

Dear Dr. Gregory Shipp,

This letter corrects our substantially equivalent letter of October 11, 2007.

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class ⅢII (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2 - Gregory W. Shipp, M.D.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0377. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Mona M Car

Maria M. Chan, Ph.D   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# 2 a. Indications for use

510(k) Number (if known): K070597

Device Name: Verigene® System

Indicatlons for Use: The Verigene System is a bench-top molecular diagnostics workstation that automates the analysis and detection of nucleic aclds using gold nanoparticle probe technology.

![](images/e06f238ed9f47fe2a2522bfd974173028ce4acefd5a66e9fecad015f6ce7bc41.jpg)

# 2 b. Indications for use

510(k) Number (if known): K070597

Device Name: Verlgene F5 Nuclelc Acld Test

Indications for Use: The Verigene F5 Nucleic Acid Test is Indicated as an aid to diagnosis in the evaluation of patients with suspected thrombophilia.

The test is an in vitro diagnostic for the detection and genotyping of a single-point mutation (G to A at position 1691; also known as Factor V Leiden) of the human Factor V gene $( F 5 ;$ Coagulation Factor V gene), from Isolated genomic DNA obtained from whole blood samples. The test is intended to be used on the Verlgene System.

![](images/453559c7f3d72c04c1037ce0df5bee6da0e2bf4ae9e44450cb64872ef9543081.jpg)

# 2 c. Indications for use

510(k) Number (if known): K070597

Device Name: Verlgene F2 Nucleic Acld Test

Indications for Use: The Verigene F2 Nucleic Acid Test is indicated as an aid to diagnosis in the evaluation of patients with suspected thrombophilia.

The test is an in vitro diagnostic for the detection and genotyping of a single-point mutation (G to A at positlon 20210) of the human Factor Il gene (F2; prothrombin gene), from isolated genomic DNA obtained from whole blood samples. The test Is intended to be used on the Verigene System.

![](images/061b1809a5b54f364c7ccf0e20a93b34a46467264c05c69a8c6240f4c34d95f9.jpg)

# 2 d. Indications for use

510(k) Number (if known): K070597

Device Name: Verigene MTHFR Nuclelc Acld Test

Indications for Use: The Verigene MTHFR Nucleic Acid Test is indicated as an aid to diagnosis in the evaluation of patients with suspected thrombophilia and elevated levels of homocysteine or altered folate metabolism.

The test is an in vitro diagnostic for the detection and genotyping of a single-point mutation (C to T at position 677) of the human 5,10 methylenetetrahydrofolate reductase gene (MTHFR), from isolated genomic DNA obtalned from whole blood samples. The test is intended to be used on the Verigene System.

Divisighn Sigfff   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) K070597